書籍詳細

●臨床編

P.17 掲載の参考文献

• 1) 辻敬一郎, 田島治:抗うつ薬によるactivation syndrome. 臨床精神薬理 8:1697-1704, 2005

• 2) 辻敬一郎, 田島治:抗うつ薬による賦活症候群(activation syndrome)と自殺関連事象. 精神科 10:2-9, 2007

P.19 掲載の参考文献

• 1) 十一元三:自閉性障害・アスペルガー障害の見方に誤りはないか. 科学 77:305-310, 2007

• 2) 十一元三:司法領域における広汎性発達障害の問題. 家庭裁判月報 58:12-1-12-42, 2006

P.21 掲載の参考文献

• 1) Gershon ES, Guroff JJ:Information from relatives. Diagnosis of affective disorders. Arch Gen Psychiatry 41:173-180, 1984
  pubmed

• 2) 岡崎祐士, 伊東勉, 藤丸浩輔ほか:The Family Interview for Genetic Studies (FIGS). 分子精神医学 5:159-170, 2005
  Medical*Online

P.23 掲載の参考文献

• 1) 山上皓:触法精神障害者をめぐる諸問題. 精神経誌 100:958-975, 1998

• 2) 武井満:精神保健福祉法通報制度の問題点と司法精神医学的課題. 精神医学 44:619-625, 2002

• 3) http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/170815aq.pdf

• 4) http://wwwhourei.mhlw.go.jp/hourei/doc/tsuchi/170815ar.pdf

• 5) http://www.ncnp-k.go.jp/dshihou/monitoring/D/6.pdf

P.25 掲載の参考文献

• 1) 久保千春:うつ病は身体疾患の発症や予後を左右する. 医学の歩み 219:1125-1128, 2006

• 2) van Melle JP, de Jonge P, Spijkerman TA et al:Prognostic association of depression following myocardial infarction with mortality and cardiovascular events:A meta-analysis. Psychosom Med 66:814-822, 2004
  pubmed

• 3) Carney RM, Blumenthal JA, Freedland KE et al:Depression and late mortality after myocardial infarction in the Enhancing Recovery in Coronary Heart Disease (ENRICHD) study. Psychosom Med 66:466-474, 2004
  pubmed

P.27 掲載の参考文献

• 1) 西尾雅明:ACT入門-精神障害者のための包括型地域生活支援プログラム, 金剛出版, 東京, 2004

• 1) デボラRベッカー, ロバートEドレイク:精神障害をもつ人たちのワーキングライフ IPSチームアプローチに基づく援助付き雇用ガイド, 大嶋巌, 松為信雄, 伊藤順一郎監訳, 金剛出版, 東京, 2004

• 2) 西尾雅明:ACT導入に伴う統合失調症治療技法の変化. 臨床精神薬理 7:21-28, 2004

• 3) 伊藤順一郎, 西尾雅明, 大嶋巌ほか:日本版ACT (ACT-J) 研究事業の成果と今後の展望. 精神医学 47:1345-1352, 2005

P.30 掲載の参考文献

• 1) 齊藤万比古, 渡部京太編:改訂版注意欠陥/多動性障害-AD/HD-の診断. 治療ガイドライン, じほう, 東京, 2006

• 1) Barkley RA:Attention-Deficit Hyperactivity Disorder. A Handbook for Diagnosis and Treatment, 3rd ed, The Guilford Press, London, 2006

P.33 掲載の参考文献

• 1) Simon GE, Savarino J, Operskalski B et al:Suicide risk during antidepressant treatment. Am J Psychiatry 163:41-47, 2006
  pubmed

• 1) Hall WD, Lucke J:How have the selective serotonin reuptake inhibitor antidepressants affected suicide mortality? Aust N Z J Psychiatry 40:941-950, 2006
  pubmed

• 2) Rihmer Z, Akiskal H:Do antidepressants t(h)reat(en) depressives? Toward a clinically judicious formulation of the antidepressant-suicidality FDA advisory in light of declining national suicide statistics from many countries. J Affect Disord 94:3-13, 2006

• 2) Juurlink DN, Mamdani MM, Kopp A et al:The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 163:813-21, 2006
  pubmed

• 3) 辻敬一郎, 田島治:抗うつ薬によるactivation syndrome. 臨床精神薬理 8:1697-1704, 2005

P.34 掲載の参考文献

• 1) Endicott J, Andreasen NC, Spitzer RL:Family History-Research Diagnostic Criteria (FH-RDC), 3rd ed, New York State Psychiatric Institute, New York, 1978

• 2) Spitzer RL, Endicott J:Schedule for affective disorders and schizophrenia (SADS), 3rd ed, New York State Psychiatric Institute, New York, 1979 保崎秀夫監訳, 北村俊則, 加藤元一郎, 峰尾英子ほか共訳:感情病および精神分裂病用面接基準, 星和書店, 東京, 1983

• 3) Spitzer RL, Endicott J, Robins E:Research Diagnostic Criteria (RDC) for a selected group of functional disorders, 3rd ed, New York State Psychiatric Institute, New York, 1978 本多裕, 岡崎祐士監訳, 安西信雄, 平松謙一, 亀山知道ほか共訳:精神医学研究用診断マニュアル, 国際医書出版, 東京, 1981

• 4) Endicott J, Andreasen NC, Spitzer RL 著:加藤元一郎, 北村俊則訳, 家族歴研究診断基準 (FH-RDC). 社会精神医学8:55-64, 1985

• 5) 北村俊則, 島悟, 峰尾英子ほか:症例要旨法による家族歴研究診断基準(FH-RDC)の信頼度検定. 社会精神医学7:308-312, 1984

P.37 掲載の参考文献

• 1) 矢部博興:Mismatch negativityの反映する感覚記憶の研究とその臨床的意義. 精神経誌 106:1-16, 2004

• 2) 笠井清登, 川久保友紀, 管心:ミスマッチネガティビティー統合失調症の情報処理.Schizophrenia Frontier 6:89-95, 2005

• 3) Shelley AM, Ward PB, Catts SV et al:Mismatch negativity:an index of a preattentive processing deficit in schizophrenia. Biol Psychiatry 30:1059-1062, 1991
  pubmed

• 4) Umbricht D, Krljes S:Mismatch negativity in schizophrenia:a meta-analysis. Schizophr Res 76:1-23, 2005
  pubmed

• 5) Light GA, Braff DL:Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry 62:127-136, 2005
  pubmed

• 6) Yamasue H, Yamada H, Yumoto M et al:Abnormal association between reduced magnetic mismatch field to speech sounds and smaller left planum temporale volume in schizophrenia. Neuroimage 22:720-727, 2004

• 7) Kasai K, Nakagome K, Iwanami A et al:Neuro-psychiatry and the auditory selective attention process. Curr Opin Psychiatry 14:219-225, 2001

P.39 掲載の参考文献

• 1) Salloway S, Ferris S, Kluger A et al:Efficacy of donepezil in mild cognitive impairment:a randomized placebo-controlled trial. Neurology 63:651-657, 2004
  pubmed

• 1) Petersen RC, Smith GE, Waring SC et al:Mildcognitive impairment:clinical characterization and outcome. Arch Neurol 56:303-308, 1999

• 2) American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), 4th ed, Washington DC, 1994

• 3) Levy R:Ageing-associated cognitive decline. Working Party of the International Psychogeriatric Association in collaboration with the World Health Organization. Int Psychogeriatr 6:63-68, 1994
  pubmed

P.42 掲載の参考文献

• 1) 朝倉聡, 井上誠士郎, 佐々木史ほか:Liebowitz Sosial Anxiety Scale (LSAS) 日本語版の信頼性および妥当性の検討. 精神医学 44:1077-1084, 2002

• 1) Mennin DS, Fresco DM, Heimberg RG et al:Screening for social anxiety disorder in the clinical setting:using the Liebowitz Social Anxiety Scale. J Anxiely Disord 16:661-673, 2002

P.45 掲載の参考文献

• 1) 田村義之, 千葉茂:成人におけるサーカディアンリズム睡眠障害. サーカディアンリズム睡眠障害の臨床, 千葉茂, 本間研一編著, 新興医学出版社, 東京, 2003, pp. 46-48

• 2) 大川匡子:時間生物学的治療法. 臨床睡眠医学, 塩澤全司, 大川匡子, 太田龍朗編, 朝倉書店, 東京, 1999, p.52-56

P.49 掲載の参考文献

• 1) Tournier-Lasserve E, Joutel A, Melki J et al:Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy maps to chromosome 19 q 12. Nature Genetics 3:256-259, 1993

• 2) Dichgans M, Mayer M, Uttner I et al:The phenotypic spectrum of CADASIL:clinical findings in 102 cases. An Neztrol 44:731-739, 1998
  pubmed

• 3) Adachi Y, Nakashima K:Cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) characteristics in Japan:variety of clinical features. Intern Med 39:681-682, 2000
  pubmed

• 4) Joutel A, Vahedi K, Corpechot C et al:Strong clustering and stereotyped nature of Notch 3 mutations in CADASIL patients. Lancet 350:1511-1515, 1997

P.51 掲載の参考文献

• 1) Jobsis FF:Noninvasive infrared monitoring of cerebral and myocardial oxygen sufficiency and circulatory parameters. Science 198:1264-1267, 1977
  pubmed

• 2) Hoshi Y:Functional near-infrared spectroscopy:Potential and limitations in neuroimaging studies. In:Neuroimaging Part A:International Review of Neurobiology, ed by Glabus MF, Elsevier Academic Press, NY, 2005, pp.238-266

P.53 掲載の参考文献

• 1) Lieberman JA, Stroup TS, McEvoy Jp et al;Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators:Effectiveness of anti-psychotic drugs in patients with chronic schizophrenia. N Engl J Med 353:1209-1223, 2005

• 2) Lieberman JA:慢性統合失調患者における抗精神病薬の有効性. 臨床精神薬理 9:2285-2299, 2006

• 3) Kane JM, Leucht S, Carpenter D et al:The Expert Consensus Guideline Series. Optimizing Pharmacologic Treatment of Psychotic Disorders. J Clin Psychiatry 64 (suppl 12):S2-S 97, 2003

• 4) Glick ID:Understanding the results of CATIE in the context of the field. CNS Spectr 11 (7 suppl 7):S40-S47, 2006

P.54 掲載の参考文献

• 1) Lassenius B, Osterman E:[Complications in prolonged chlorpromazine therapy;preliminary report.] Nord Med 55:798-801, 1956
  pubmed

• 2) Cooperberg AA, Eidlow S:Haemolytic anemia, jaundice and diabetes mellitus following chlorpromazine therapy. Can Med Assoc J 75:746-749, 1956
  pubmed

• 3) 大熊輝雄, 八木剛平, 山下格ほか:精神分裂病に対するKD-136(デカン酸ハロペリドール:持効剤)の第III相試験-ハロペリドール経口剤を対照とした多施設二重盲検比較試験に関する解析の詳細-. 臨床評価 15:37-72, 1987

• 4) 村崎光邦, 三浦定則, 山下格ほか:精神分裂病に対する新規抗精神病薬Risperidoneの臨床評価-Haloperidolを対照薬とした第III相試験-. 臨床評価21:221-259, 1993

• 5) 石郷岡純:我が国における olanzapine の臨床試験成績. 臨床精神薬理 4:945-955, 2001

• 6) Wettering T:Bodyweight gain with atypical antipsychotics. A comparative review. Drag Saf 24:59-73, 2001

• 7) Marder SR, McQuade RD, Stock E et al:Aripiprazole in the treatment of schizophrenia:safety and tolerability in short-term, placebo-controlled trials. Schizophr, Res 61:123-136, 2003
  pubmed

• 8) Lambert BL, Cunningham FE, Miller DR et al:Diabetes risk associated with use of olanzapine, quetiapine, and risperidone in veterans health administration patients with schizophrenia. Am J Epidemiol 164:672-681, 2006
  pubmed

P.57 掲載の参考文献

• 1) Spitzer RL, Williams JB, Gibbon M et al:The Structured Clinical Interview for DSM-III-R (SCID). I:History, rationale, and depression. Arch Gen Psychiatry 49:624-629, 1992

• 2) 高橋三郎監修:精神科診断面接マニュアルSCID, 日本評論社, 東京, 2003

• 3) The Composite International Diagnostic Interview (CIDI), Authorized Core Version 1. 0. World Health Organization (WHO), Geneva, 1990

P.58 掲載の参考文献

• 1) Premack D, Woodruff G:"Does the Chimpanzee Have a Theory of Mind?". Behav Brain Sci 4:515-526, 1978

• 2) 杉山登志郎:アスペルガー症候群と心の理論. 精神科治療学 14:47-52, 1999

• 3) Wellman HM, Cross D, Watson J:Meta-analysis of theory-of-mind development:the truth about false belief. Child Dev 72:655-684, 2001
  pubmed

• 4) Brune M, Brune-Cohrs U:Theory of mind--evolution, ontogeny, brain mechanisms and psychopathology. Neurosci Biobehav Rev 30:437-455, 2006
  pubmed

P.62 掲載の参考文献

• 1) Timpl P, Spanagel R, Sillaber I et al:Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat Genet 19:162-166, 1998

• 1) Holsboer F:The rationale for corticotropinreleasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiat Res 33:181-214, 1999
  pubmed

• 2) 大嶋明彦, 樋口輝彦, 上島国利:CRHアンタゴニスト新規抗うつ薬の可能性-. 分子精神医学 3:26-31, 2003

• 2) Smith GW, Aubry JM, Dellu F et al:Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20:1093-1102, 1998
  pubmed

• 3) Muller MB, Zimmermann S, Sillaber I et al:Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat Neurosci 6:1100-1107, 2003
  pubmed

• 3) Muller MB, Wurst W:Getting closer to affective disorders:the role of CRH receptor systems. Trends Mol Med 10:409-415, 2004
  pubmed

• 4) Muller MB, Holsboer F:Mice with mutations in the HPA-system as models for symptoms of depression. Biol Psychiatry 59:1104-1115, 2006
  pubmed

• 4) Keck ME, Welt T, Wigger A et al:The anxiolytic effect of the CRH (1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 13:373-380, 2001
  pubmed

• 5) Heinrichs SC, De Souza EB, Schulteis G et al:Brain penetrance, receptor occupancy and antistress in vivo efficacy of a small molecule corticotropin releasing factor type I receptor selective antagonist. Neuropsychopharmacology 27:194-202, 2002
  pubmed

• 6) Arborelius L, Skelton KH, Thrivikraman KV et al:Chronic administration of the selective corticotropin releasing factor 1 receptor antagonist CP-154,526:behavioral, endocrine and neurochemical effects in the rat. J Pharmacol Exp Ther 294:588-597, 2000

• 7) Griebel G, Simiand J, Steinberg R et al:4-(2-Chloro-4-methoxy-5-methylphenyl)-N[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl] 5-methyl-N-(2-propynyl)-1, 3-thiazol-2-amine hydrochloride(SSR 125543 A), a potent and selective corticotrophin-releasing factor(1) receptor antagonist. II. Characterization in rodent models of stress-related disorders. J Pharmacol Exp Ther 301:333-345, 2002

• 8) Ayala AR, Pushkas J, Higley JD et al:Behavioral, adrenal, and sympathetic responses to long-term administration of an oral corticotropin-releasing hormone receptor antagonist in a primate stress paradigm. J Clin Endocrinol Metab 89:5729-5737, 2004

• 9) Isogawa K, Akiyoshi J, Hikichi T et al:Effect of corticotropin releasing factor receptor 1 antagonist on extracellular norepinephrine, dopamine and serotonin in hippocampus and prefrontal cortex of rats in vivo. Neuropeptides 34:234-239, 2000
  pubmed

• 10) 0shima A, Flachskamm C, Reul JM et al:Altered serotonergic neurotransmission but normal hypothalamic-pituitary-adrenocortical axis activity in mice chronically treated with the corticotropinreleasing hormone receptor type 1 antagonist NBI 30775. Neuropsychopharmacology 28:2148-2159, 2003
  pubmed

• 11) Zobel AW, Nickel T, Kunzel HE et al:Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression:the first 20 patients treated. J Psychiatr Res 4:171-181, 2000

P.69 掲載の参考文献

• 1) Brothers L:The social brain:a project for integrating primate behavior and neurophysiology in a new domain. Concept Neztrosci 1:27-51, 1990

• 2) 井上由美子, 山田和男, 神庭重信:社会脳 (Social brain). 分子精神医学 4:1-6, 2004

• 3) 井上由美子, 山田和男, 神庭重信:「社会脳」と「心の理論」. 分子精神医学 4:7-11, 2004

• 4) Inoue Y, Yamada K, Tonooka Y et al:Deficiency of theory of mind in patients with remitted mood disorders. J Affect. Disord 82:403-409, 2004
  pubmed

• 5) Inoue Y, Yamada K, Hirano M et al:Impairment of theory of mind in patients in remission following first episode of schizophrenia. Eur Arch psychiatry Clin Neurosci 256:326-328, 2006
  pubmed

• 6) Inoue Y, Yamada K, Kanba S:Deficit in theory of mind is a risk for relapse of major depression. J Affect Disord 95:125-127, 2006
  pubmed

P.71 掲載の参考文献

• 1) American Psychiatric Association:DSM-IV-TR 精神疾患の分類と診断の手引, 高橋三郎, 大野裕, 染矢俊幸訳, 医学書院, 東京, 2003, pp.176-177

• 1) Schneier F:Social Anxiety Disorder. N Engl J Med 355:1029-1036, 2006
  pubmed

• 2) 朝倉聡, 小山司:社会不安障害に対するSSRIの効果. 社会不安障害治療のストラテジー, 小山司編, 先端医学社, 東京, 2005, pp.139-144

P.72 掲載の参考文献

• 1) 宮永和夫:若年期の痴呆の疫学. 老年精神医学9:1439-1449, 1998

• 2) Yokota O, Sasaki K, Fujisawa J et al:Frequency of early and late-onset dementias in a Japanese memory disorders clinic. Er J Neurol 12:782-790, 2005

• 3) 若年期痴呆介護の実態調査報告書, 呆け老人をかかえる家族の会 (編集・発行), 京都, 2002

P.75 掲載の参考文献

• 1) Cox JL, Holden JM, Sagovsky R:Detection of postnatal depression. Development of the 10-item Edinburgh Postnatal Depression Scale. Br J Psychiatry 150:782-786, 1987
  pubmed

• 2) 岡野禎治, 村田真理子, 増地聡子ほか:日本版エジンバラ産後うつ病自己評価票(EPDS)の信頼性と妥当性. 精神科診断学 7:525-533, 1996

• 3) 山下洋, 吉田敬子:産後うつ病の母親のスクリーニングと介入について. 精神経誌105:1129-1135, 2003

• 4) 山下洋, 吉田敬子:妊娠期における向精神薬の使用について-児の発達学的観点からのリスクの検討-. 臨床精神医学 33:1011-1026, 2004
  Medical*Online

• 5) 吉田敬子:21世紀の乳幼児医学・心理学の今後の方向-周産期精神医学からの提示 . 乳幼児医学・心理学研究 14:11-25, 2005

• 6) Glover V, Thomas G, O'Connor ;吉田敬子訳:出産前の母親のストレスや不安が子どもに与える長期的影響. 臨床精神医学 33:983-994, 2004

• 7) 吉田敬子, 山下洋, 岩元澄子:周産期における精神科薬物療法のリスクと利益. 育児支援のチームアプローチ-周産期精神医学の理論と実践-, 吉田敬子編, 金剛出版, 東京, 2006, pp.31-56

P.81 掲載の参考文献

• 1) 宮本聖也:第一世代薬と第二世代薬ではどう違うのか. チームで変える! 第二世代抗精神病薬による統合失調症治療, 石郷岡純総編集, 中山書店, 東京, 2006, pp.29-44

• 2) 諸川由実代, 青葉安里:統合失調症治療戦略の新しい展開. 臨床精神薬理 7:1699-1705, 2004

• 3) Stahl SM:精神科治療薬処方ガイド, 仙波純一訳, メディカル・サイエンス・インターナショナル, 東京, 2006

• 4) Taylor D, Paton C, Kerwin R:The Maudsley 2005-2006 Prescribing Guidelines, 8th ed, Taylor & Francis Group, London, 2005, pp.7-106

P.83 掲載の参考文献

• 1) National Institute of Mental Health (NIMH) ホームページ:Results for Sequenced Treatment Alternatives to Relieve Depression (STAR*D) Study, http://gopher.nimh.nih.gov/healthinformation/stard.cfm

• 2) Rush AJ, Fava M, Wisniewski SR et al:STAR*D Investigators Group. Sequenced treatment alternatives to relieve depression (STAR*D):rationale and design. Control Clin Trials 25:119-142, 2004

• 3) Nierenberg AA, Trivedi MH, Ritz L et al:Suicide risk management for the sequenced treatment alternatives to relieve depression study:applied NIMH guidelines. J Psychiatr Res 38:583-589, 2004
  pubmed

• 4) Rush AJ, Trivedi MH, Wisniewski SR et al:STAR*D Study Team. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. N Engl J Med 354:1231-1242, 2006
  pubmed

• 5) Rush AJ, Trivedi MH, Wisniewski SR et al:Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps:a STAR* Dreport. Am J Psychiatry 163:1905-1917, 2006

P.85 掲載の参考文献

• 1) Sachs GS:Strategies for improving treatment of bipolar disorder:integration of measurement and management. Acta Psychiatr Scand Suppl 422:7-17, 2004
  pubmed

• 2) Sachs GS, Thase ME, Otto MW et al:Rationale, design, and methods of the systematic treatment enhancement program for bipolar disorder (STEP-BD). Biol Psychiatry 53:1028-1042, 2003
  pubmed

• 3) 織部直弥, 三浦智史, 川嵜弘詔:STEP-BD:米国NIMH双極性障害の縦断的治療研究【双極性障害】. 臨床精神医学35:1417-1422, 2006

P.87 掲載の参考文献

• 1) Fragile X Syndrome:Diagnosis, Treatment, and Research, 3rd ed, ed by Hagerman RJ, Hagerman PJ, Johns Hopkins Univ Press, Baltimore, 2002

• 2) O'Donnell WT, Warren ST:A decade of molecular studies of fragile X syndrome. Annu Rev Neurosci 25:315-338, 2002
  pubmed

• 3) Hagerman RJ, Ono MY, Hagerman PJ:Recent advances in fragile X:a model for autism and neurodegeneration. Curr Opin Psychiatry 18:490-496, 2005

P.89 掲載の参考文献

• 1) 伊藤弘人:米国の精神科入院医療の支払方式. 日精協誌 21:1232-1235, 2002

• 2) 岸泰弘, ロジャー・ケーソル:精神科と包括支払方式-精神科にDRG(DPC)を免除することの問題点. 社会保険旬報2187 (2003.10.21):2003

• 3) 松田晋哉:臨床医のためのDPC入門-Q&Aで学ぶDPCの基礎知識100, じほう, 東京, 2006

P.91 掲載の参考文献

• 1) Akiskal HS:The bipolar spectrum:New concepts in classification and diagnosis. In:The American Psychiatric Association Annual Review, ed by Grinspoon L, Amer Psychiatric Pub, Washington DC, 1983, pp. 271-292

• 2) Akiskal HS, BitarAH, PusantianVR et al:The nosological states of neurotic depression:a prospective 3-4 year follow-up examination in light of the primary-secondary and unipolar-bipolar dichotomies. Arch Gen Psychiatry 35:756-766, 1978

• 3) 内海健:双極II型障害の臨床. 治療の聲 2:267-278, 1999

• 4) 内海健:うつ病新時代-双極II型障害という病, 勉誠出版, 東京, 2006

• 5) Akiskal HS, Maser JD, Zeller PJ et al:Switching from'unipolar'to bipolar II:An 11-year prospective study of clinical and temperamental predictors in 559 patients. Arch Gen Psychiatry 52:114-123, 1995

• 6) Akiskal HS:Bipolar II:Prevalence and clinical significance of the soft bipolar spectrum. In:IX world co ngress of Psychiatry. World Scientific, River Edge, New Jersey, 1994, pp.275-279

• 7) Akiskal HS:Soft Bipolarity-A footnote to Kraepelin 100 years later. 第22回日本精神病理学会, 東京, 1999 (広瀬徹也訳:臨床精神病理18:3-11, 2000)

• 8) 内海健:うつ状態. 臨床精神医学26巻増刊号 精神神経疾患の状態像と鑑別診断, アークメディア, 東京, 1997, pp. 39-44

P.93 掲載の参考文献

• 1) Klerman GL, Weissman MM, Rounsaville BJ et al:Interpersonal Psychotheraphy of Depression, Basic Books, New York, 1984 (水島広子, 嶋田誠, 大野裕訳:うつ病の対人関係療法, 岩崎学術出版社, 東京, 1997)

• 2) Weissman MM, Markowitz JC, Klerman GL:Comprehensive Guide to Interpersonal Psychotherapy, Basic Books, New York, 2000

• 3) Wilfley DE, MacKenzie KR, Welch RR et al:Interpersonal Psychotherapy for Group, Basic Books, New York, 2000 (水島広子訳:グループ対人関係療法, 創元社, 大阪, 2006)

P.94 掲載の参考文献

• 1) Awata S, Bech P, Koizumi Y et al:Validity and utility of the Japanese version of the WHO-Five Well-Being Index in the context of detecting suicidal ideation in elderly community residents. Int Psychogeriatr 19:77-88, 2007

• 2) Awata S, Bech P, Yoshida S et al:Reliability and validity of the Japanese version of the World Health Organization-Five Well-Being Index in the context of detecting depression in diabetic patients. Psychiatry Clin Neurosci 61:112-119, 2007
  pubmed

P.96 掲載の参考文献

• 1) 石郷岡純:ベンゾジアゼピン系睡眠薬の副作用と処方上の留意点. 臨床精神医学講座第13巻睡眠障害, 松下正明ほか編, 中山書店, 東京, 1999, pp.148-157

• 1) 石郷岡純:ベンゾジアゼピンと常用量依存. 治療学 28:1005-1008, 1994
  Medical*Online

• 2) 辻敬一郎:ベンゾジアゼピンの依存と離脱症状. 臨床精神医学 35:1669-1674, 2006
  Medical*Online

• 3) Warner CH, Bobo W, Warner C et al:Antidepressant discontinuation syndrome. Am Fam Physician 74:449-456, 2006
  pubmed

P.99 掲載の参考文献

• 1) Hafner H, Reicher-Rossler A, Hambrecht M et al:IRAOS:an instrument for the assessment of onset and early course of schizophrenia. Schizopher Res 6:209-223, 1992

• 2) Yamazawa R, Mizuno M, Nemoto T et al:Duration of untreated psychosis and pathways to psychiatric services in first-episode schizophrenia. Psychiatry Clin Neurosci 58:76-81, 2004
  pubmed

• 3) 水野雅文, 山澤涼子:初回エピソード分裂病の未治療期間 (DUP) と治療予後. Schizophrenia Front 3:35-39, 2002
  Medical*Online

• 4) Morgan C, Abdul-Al R, Lappin J et al:Clinical and social determinants of duration of untreated psychosis in the AESOP first-episode psychosis study. Br J Psychiatr 189:446-452, 2006

P.101 掲載の参考文献

• 1) Guntrip H:Schizoid phenomena, obiect relations and the self, International Universities Press, New York, 1969

• 2) Kretschmer E:Korperbau und Charakter. Springer-Verlag, Berlin, 1926 (相場均訳:体格と性格, 文光堂, 東京, 1960)

• 3) Kalus O, Bernstein DP, Siever LJ:Schizoid personality disorder. In:DSM-IV Sourcebook, American Psychiatric Publishing, Washington DC, 1998, pp.675-684

• 4) Millon T, Davis RD:Disorders of personality:DSM-IV and bayond, and beyond,2nd edition, Wiley & Sons, New York, 1996

P.103 掲載の参考文献

• 1) Hirose T, Kikuchi T:Aripiprazole, a novel anti psychotic agent:dopamine D2 receptor partial agonist. J Med Invest 52 (suppl):S 284-S 290, 2005

• 2) Shapiro DA, Renock S, Arrington E et al:Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 28:1400-1411, 2003
  pubmed

• 3) El-Sayeh HG, Morganti C:Aripiprazole for schizophrenia. Cochrane Database Syst Rev 19:CD 004578, 2006

P.105 掲載の参考文献

• 1) McCullough JP:慢性うつ病患者とCBASPプログラムについての序説. 慢性うつ病の精神療法, 古川壽亮, 大野裕, 岡本泰昌ほか監訳, 医学書院, 東京, 2006, pp.6-24

• 2) Keller MB, McCullough JP, Klein DN et al:A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 342:1462-1470, 2000
  pubmed

• 3) Klein DN, Santiago NJ, Vivian D et al:Cognitive-behavioral analysis system of psychotherapy as a maintenance treatment for chronic depression. J Consult Clin Pshchol 72:681-688, 2004
  pubmed

P.107 掲載の参考文献

• 1) Liberman RP, Glynn S, Blair KE et al:In vivo amplified skills training:promoting generalizarion of independent living skills for clients with schizophrenia. Psychiatry 65:137-155, 2002
  pubmed

• 2) 井上新平, 安西信雄, 池淵恵美監修, 佐藤さやか, 森田慎一訳, Liberman RPほか原著:日本版精神障害を持つ人の退院準備プログラム, 丸善出版事業部, 東京, 2006

• 3) Pfammatter M, Junghan UM, Brenner HD:Efficacy of psychological therapy in schizophrenia:conclusion from meta-analysis. Schizophr Bull 32 (suppl 1):S 64-S 80, 2006

P.111 掲載の参考文献

• 1) Shear MK, Brown TA, Barlow DH et al:Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571-1575, 1997
  pubmed

• 2) Wolfe BE, Maser JD:Treatment of panic disorder:A consensus development conference, American Psychiatric Press, Washington DC, 1994

• 3) Yamamoto I, Nakano Y, Furukawa T et al:Cross-cultual evaluation of the Panic Disorder Severity Scale in Japan. Depress Anxiety 20:17-22, 2004

• 4) 高塩理, 大坪天平, 上島国利ほか:Panic Disorder Severity Scale 日本語版(PDSS-J)の妥当性と反応性. 臨床精神薬理 7:1155-1168, 2004

P.114 掲載の参考文献

• 1) 篠崎和弘, 上山栄子, 松本直起:ECTとrTMSによるうつの治療. 脳と精神の医学 17:223-230, 2007

• 2) Mayberg HS, Lozano AM, Voon V et al:Deep brain stimulation for treatment-resistant depression. Neuron 45:651-660, 2005
  pubmed

• 3) Burt T, Lisanby SH, Sackeim HA:Neuropsychiatric applications of transcranial magnetic stimulation:a meta analysis. Int J Neuropsychopharmacol 5:73-103, 2002
  pubmed

• 4) Loo CK, Mitchell PB:A review of the efficacy of transcranial magnetic stimulation (TMS) treatment for depression, and current and future strategies to optimize efficacy. J Affect Disord 88:255-267, 2005
  pubmed

• 5) Rossini D, Lucca A, Zanardi R et al:Transcranial magnetic stimulation in treatment-resistant depressed patients:a double-blind, placebo-controlled trial. Psychiatry Res 137:1-10, 2005
  pubmed

• 6) Machii K, Cohen D, Ramos-Estebanez C et al:Safety of rTMS to non-motor cortical areas in healthy participants and patients. Clin Neurophysiol 117:455-471, 2006
  pubmed

P.117 掲載の参考文献

• 1) Holden C:"Behavioral addictions";do they exist? Science 294:980-982, 2001
  pubmed

• 1) 高橋三郎, 大野裕, 染矢俊幸訳:DSM-IV 精神疾患の分類と診断の手引, 医学書院, 東京, 2003

• 2) Hollander E, Wong CM:Obsessive-compulsive spectrum disorders. J Clin Psychiatry 56 (suppl 4):S3-S6, 1995

• 3) Black DW, Monahan PO, Temkit MH et al:A family study of pathological gambling. Psychiatr Res 141:295-303, 2006

• 4) Lobo DSS, Kennedy JL:The genetics of gambling and behavioral addictions. CNS Spectr 11:931-939, 2006
  pubmed

• 5) Grant JE, Brewer JA, Potenza MN:The neuro-biology of substance and behavioral addictions. CNS Spectr 11:924-930, 2006

• 6) Potenza MN, Steinberg MA, Skudlarski P et al:Gambling urges in pathological gambling:a functional magnetic resonance imaging study. Arch Gen Psychiatry 60:828-836, 2003
  pubmed

• 7) 松下幸生, 樋口進:ギャンブル依存の精神医学. 精神科 8:464-470, 2006

• 8) 松澤信彦:病的賭博 (ギャンブル依存症). 臨床精神医学 34:165-171, 2005
  Medical*Online

P.120 掲載の参考文献

• 1) Hahn SR, Sydney E, Kroenke K et al:Evaluation of Mental Disorders with the Primary Care Evaluation of Mental Disorders and Patients Health Questionnaire. In:The Use Of Psychological Testing for Treatment Planning and Outcomes Assessment. 3rd edition, ed by Maruish ME, Lawrence Erlbaum Associate Inc Publishers, New Jersey, 2004, pp.235-291

• 2) Spitzer RL, Williams JB, Kroenke K et al:Utility of a new procedure for diagnosing mental disorders in primary care:the PRIME-MD 1000 study. JAMA 272:1749-1756, 1994
  pubmed

• 3) Spitzer RL, Kroenke K, Williams JB et al:Validation and utility of a self-report version of PRIME-MD:the PHQ primary care study. Primary Care Evaluation of Mental Disorders. Patient Health Questionnaire. JAMA 282:1737-1744, 1999
  pubmed

• 4) 村松公美子:プライマリケアにおける精神疾患の疫学. EBM ジャーナル 5:512-517, 2004
  Medical*Online

P.124 掲載の参考文献

• 1) 木谷照夫, 倉恒弘彦:慢性疲労症候群. 日本内科学会雑誌 81:573-582, 1992

• 2) 倉恒弘彦:臨床的側面 慢性疲労症候群と帯状回. Clin Neurosci 23:1286-1291, 2005

• 3) 特集;慢性疲労症候群(CFS)研究の進歩と診療への手引き, 倉恒弘彦編, Prog Med 25:1229-1339, 2005

• 4) Fukuda K, Straus SE, Hickie I et al:The chronic fatigue syndrome:a comprehensive approach to its definition and study. Ann Intern Med 121:953-959, 1994
  pubmed

P.127 掲載の参考文献

• 1) Sheehan DV, Lecrubier Y, Sheehan KH et al:The Mini International Neuropsychiatric Interview (M.I.N.I.):the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 59 (suppl 20):S 22-S 33, 1998

• 2) 大坪天平, 宮岡等, 上島国利訳:M.I.N.I. 精神疾患簡易構造化面接法 (2003), 星和書店, 東京, 2003

• 3) Otsubo T, Tanaka K, Koda R et al:Reliability and validity of Japanese version of Mini-International Neuropsychiatric Interview. Psychiatry Clin Neuro-sci 59:517-526, 2005

P.128 掲載の参考文献

• 1) 本橋伸高:ECTマニュアルー科学的精神医学をめざして, 医学書院, 東京, 2000

• 2) 安田和幸, 本橋伸高:電気けいれん療法. 臨床精神神経薬理学テキスト, 日本臨床精神神経薬理学会 専門医制度委員会編, 星和書店, 東京, 2006, pp.305-314

• 3) Royal College of Psychiatrists:The ECT Handbook:The Third Report of the Royal College of Psychiatrists' Special Committee on ECT, Royal College of Psychiatrists, London, 2005

• 4) American Psychiatric Association Committee on Electroconvulsive Therapy:The Practice Of Electroconvulsive Therapy:Recommendations for Treatment,Training,and Privileging, 2nd ed, American Psychiatric Association, Washington DC, 2001 (日本精神神経学会 電気けいれん療法の手技と適応基準の検討小委員会監訳:米国精神医学会タスクフォースレポートECT実践ガイド, 医学書院, 東京, 2002)

P.132 掲載の参考文献

• 1) 宇野正威, 朝田隆, 高山豊ほか:もの忘れ外来 武蔵病院におけるアルツハイマー病早期診断-. 老年精神医学雑誌,11:1195-1202, 2000
  Medical*Online

• 2) 宇野正威:わが国におけるもの忘れ外来-その歴史的レビュー-. 老年精神医学雑誌15 (suppl):S 117-S 122, 2004

• 3) 今井幸充:もの忘れ外来・認知症外来の現況-認知症の治療・介護システムのなかでの位置づけ-. 老年精神医学雑誌 16:1337-1343, 2005

• 4) 有馬邦正, 児玉千稲, 大西隆ほか:武蔵病院もの忘れ外来のMCI患者の継続的観察. 厚生労働省長寿科学総合研究事業, 軽度認知障害の前方視的・後方視的研究 (主任研究者 村山繁雄), 平成16年度総括・分担研究報告書2005年3月, pp.23-28

P.135 掲載の参考文献

• 1) 厚生労働省補償課:精神障害等の労災補償状況, 2004

• 2) 労働省労働基準局補償課職業病認定対策室:心理的負荷による精神障害等に係わる業務上外の判断指針について, 1999

• 3) World Health Organization:The ICD-10 Classification of Mental and Behavioural Disorders:Diagnostic criteria for research (融道夫, 中根允文, 小宮山実訳:ICD-10精神および行動の障害臨床記述と診断ガイドライン, 医学書院, 東京, 1993)

• 4) World Health Organization:The ICD-10 Classification of Mental and Behavioural Disorders:Clinical Descriptions and Diagnostic Guidelines (中根允文, 岡崎祐士, 藤原妙子訳:ICD-10精神および行動の障害 DCR研究用診断基準, 医学書院, 東京, 1994)

P.137 掲載の参考文献

• 1) Pascual-Marqui RD, Michel CM, Lehmann D:Low resolution electromagnetic tomography:a new method for localizing electrical activity in the brain. Int J Psychophysiol 18:49-65, 1994
  pubmed

• 2) Pascual-Marqui RD:Review of methods for solving the EEG inverse problem. Int J Bioelectmagnet 1:75-86, 1999

• 3) Pascual-Marqui RD, Esslen M, Lehmann D et al:Functional imaging with low-resolution brain electromagnetic tomography (LORETA):a review. Methods Find Exp Clin Pharmacol 24 (suppl C):S 91-S 95, 2002

• 4) 中村真樹 (研究協力者), 松岡洋夫 (主任研究者):分担研究報告 LORETA (Low-Resolution Electromagnetic Tomography) による精神分裂病における直接プライミング異常の解析. 厚生労働科学研究費補助金 (こころの健康科学研究事業) 精神分裂病の発症 脆弱性の解明およびその客観的な診断方法の確立に関する研究, 平成14年度総括・分担研究報告書:2003, pp.7-28

• 5) Pascual-Marqui RD:Standardized low-resolution brain electromagnetic tomography (sLORETA):technical details. Methods Find Exp Clin Pharmacol 24 (suppl D):S 5-S 12, 2002

●基礎編

P.141 掲載の参考文献

• 1) 森和俊:波及する小胞体ストレスの概念, 実験医学 23:2760-2799, 2005

• 2) Lindholm D, Wootz H, Korhonen L:ER stress and neurodegenerative diseases. Cell Death Differ 13:385-392, 2006
  pubmed

P.143 掲載の参考文献

• 1) Kakiuchi C, Iwamoto K, Ishiwata M et al:Impaired feedback regulation of XBP 1 as a genetic risk factor for bipolar disorder. Nat Genet 35:171-175, 2003

• 2) Cichon S, Buervenich S, Kirov G et al:Lack ofsupport for a genetic association of the XBP 1 promoter polymorphism with bipolar disorder inprobands of European origin. Nat Genet 36:783-784, 2004

• 3) Hou SJ, Yen FC, Cheng CY et al:X-box binding protein 1 (XBP 1) C--116 G polymorphisms in bipolar disorders and age of onset. Neurosci Lett 367:232-234, 2004

• 4) Chen W, Duan S, Zhou J et al:A case-control study provides evidence of association for a functional polymorphism-197 C/G in XBP 1 to schizophrenia and suggests a sex-dependent effect. Biochem Biophys Res Commun 319:866-870, 2004

• 5) Kakiuchi C, Ishiwata M, Umekage T et al:Association of the XBP 1-116 C/G polymorphism with schizophrenia in the Japanese population. Psychiatry Clin Neurosci 58:438-440, 2004

• 6) Watanabe Y, Fukui N, Muratake T et al:Association study of a functional promoter polymorphism of the X-box binding protein 1 gene in Japanese patients with schizophrenia. Psychiatry Clin Neurosci 60:633-635, 2006
  pubmed

• 7) Jonsson EG, Cichon S, Schumacher J et al:Association study of a functional promoter polymorphism in the XBP 1 gene and schizophrenia. Am J Med Genet B Neuropsychiatr Genet 141:71-75, 2006

• 8) So J, Warsh JJ, Li PP:Impaired Endoplasmic Reticulum Stress Response in B-Lymphoblasts from Patients with Bipolar I Disorder.Biol Psychiatry 2007, in press

• 9) Toda H, Suzuki G, Nibuya M et al:Behavioral stress and activated serotonergic neurotransmission induce XBP-1 splicing in the rat brain. Brain Res 1112:26-32, 2006
  pubmed

• 10) Kakiuchi C, Ishiwata M, Hayashi A et al:XBP 1 induces WFS 1 through an endoplasmic reticulum stress response element-like motif in SH-SY 5 Y cells. J Neurochem 97:545-555, 2006

P.147 掲載の参考文献

• 1) Waddington CH:Principles of Embryology, ed by George Allen and Unwin Ltd, London, 1956

• 2) Nanney DL:EPIGENETIC CONTROL SYSTEMS. Proc Natl. Acad Sci USA 44:712-717, 1958
  pubmed

• 3) Wade PA:Methyl CpG-binding proteins and transcriptional repression. Bioessays 23:1131-1137, 2001
  pubmed

• 4) Amir RE, Van den Veyver IB, Wan M et al:Rett syndrome is caused by mutations in X-linked MECP2, encoding methyl-CpG-binding protein 2. Natblre Genet 23:185-188, 1999

• 5) Tsujita T, Niikawa N, Yamashita H et al:Genomic discordance between monozygotic twins discordant for schizophrenia. Am J Psyciatry 155:422-424, 1998

P.149 掲載の参考文献

• 1) Gottesman II, Gould TD:The endophenotype con cept in psychiatry:etymology and strategic intentions. Am J Psychiatry 160:636-645, 2003

• 2) Bearden CE, Freimer NB:Endophenotypes for psychiatric disorders:ready for primetime? Trends Genet 22:306-313, 2006
  pubmed

P.151 掲載の参考文献

• 1) Bodnar RJ, Klein GE:Endogenous opiates and behavior:2005. Peptides 12:3391-3478,2006
  pubmed

• 2) Uhl GR, Sora I,Wang Z:Mu opioid receptor gene, polymorphisms, variation in mu opioid receptor, nociception and opiate responses:acandidate gene for pain. Proc Natl Acad Sci USA 96:7752-7755, 1999

• 3) Ikeda K, Ide S, Han W et al:How individual sensitivity to opiates can be predicted by gene analyses. Trends Pharmacol Sci 26:311-317,2005
  pubmed

• 4) 小林秀昭, 曽良一郎:μオピオイド受容体(OPRM 1) 遺伝子多型.分子精神医学 5:64-74,2005

• 5) 曽良一郎, 渡邉秀和, 畑春実:オピオイド受容体の分子生物学.日本ペインクリニック学会誌 11:406-410, 2004.
  Medical*Online

P.152 掲載の参考文献

• 1) Davis KL, Stewart DG, Friedman JI et al:White matter changes in schizophrenia:evidence for myelin-related dysfunction. Arch Gen Psychiatry 60:443-456, 2003
  pubmed

• 2) Stewart DG, Davis KL:Possible contributions of myelin and oligodendrocyte dysfunction to schizophrenia. Int Rev Neurobiol 59:381-424, 2004
  pubmed

• 3) Iwamoto K, Kato T:Gene expression profiling in schizophrenia and related mental disorders. Neuroscientist 12:349-361, 2006
  pubmed

• 4) Woo TU, Crowell AL:Targeting synapses and myelin in the prevention of schizophrenia. Schizophr Res 73:193-207, 2005
  pubmed

P.156 掲載の参考文献

• 1) Sakurai T:The Neural Circuit of Orexin (Hypo cretin):Maintaining Sleep and Wakefulness. Nat Rev Neurosci 8:171-181, 2007

• 2) Sakurai T:Roles of orexins and orexin receptors in central regulation of feeding behavior and energy homeostasis. CNS Nezarol Disord Drug Targets 5:313-325, 2006
  pubmed

• 3) The Orexin/Hypocretin System-Physiology and Pathophysiology, ed by Nishino S, Sakurai T, Humana press, 2006

P.159 掲載の参考文献

• 1) Mansuy IM:Calcineurin in memory and bidir ectional plasticity. Biochem Biophys Res Commun 311:1195-1208, 2003

• 2) Groth RD, Dunbar RL, Mermelstein PG:Calcineurin regulation of neuronal plasticity. Biochem Biophys Res Commun 311:1159-1171, 2003
  pubmed

• 3) Lee JI, Ahnn J:Calcineurin in animal behavior. Mol Cells 17:390-396, 2004
  pubmed

P.161 掲載の参考文献

• 1) Di Marzo V, Bifulco M, De Petrocellis L:The endocannabinoid system and its therapeutic exploi-tation. Nat Rev. Drug Discov 3:771-784, 2004

• 2) Mackie K:Cannabinoid receptors as therapeutic targets. Annu Rev Pharmacol Toxicol 46:101-122, 2006
  pubmed

• 3) Ujike H, Morita Y:New perspectives in the studies on endocannabinoid and cannabis:cannabinoid receptors and schizophrenia. J Pharmacol Sci 96:376-381, 2004
  pubmed

• 4) Onaivi ES, Ishiguro H, Gong JP et al:Discovery of the presence and functional expression of can-nabinoid CB 2 receptors in brain. Ann NY Acad Sci 1074:514-536, 2006

• 5) Pazos MR, Nunez E, Benito C et al:Role of endocannabinoid system in Alzheimer's disease:new perspective. Life Sci 75:1907-1915, 2004
  pubmed

P.163 掲載の参考文献

• 1) 改訂版精神疾患100の仮説, 石郷岡純編, 星和書店, 東京, 2004, p. 14

• 1) Erhardt S, Schwieler L, Engberg G:Kynurenic acid and schizophrenia. Adv Exp Med Biol 527:155-165, 2003
  pubmed

• 2) Nilsson LK, Linderholm KR, Engberg G et al:Elevated levels of kynurenic acid in the cerebrospinal fluid of male patients with schizophrenia. Schizophr Res 80:315-322, 2005
  pubmed

• 2) Muller N, Schwarz M:Schizophrenia as an inflam-mation-mediated dysbalance of glutamatergic neurotransmission. Neurotox Res 10:131-148, 2006

P.165 掲載の参考文献

• 1) 工藤佳久:解明が進むグリア細胞の役割グリアーニューロン回路網が支える脳機能. 細胞工学特集:390-447, 2003

• 2) Ross CA, Margolis RL, Reading SA et al:Neurobiology of schizophrenia. Neuron 52:139-153, Review, 2006
  pubmed

• 3) Melone M, Vitellaro-Zuccarello L, Vallejo-Illar-ramendi A et al:The expression of glutamate transporter GLT-1 in the rat cerebral cortex is down-regulated by the antipsychotic drug clozapine. Mol Psychiatry 6:380-386, 2001

P.168 掲載の参考文献

• 1) Kojima M, Hosoda H, Date Y et al:Ghrelin is a growth hormone releasing acylated peptide from stomach. Nature 402:656-660, 1999
  pubmed

• 1) Kojima M, Kangawa K:Ghrelin:structure and function. Physiol Rev 85:495-522, 2005
  pubmed

• 2) Nakazato M, Murakami N, Date Y et al:Arole for ghrelin in the central regulation of feeding. Nature 409:194-198, 2001

• 2) 中原桂子, 村上昇, 寒川賢治:グレリンとニューロメジンUの生理作用の探索と臨床応用への可能性について. 獣医生化学雑誌 41:39-50, 2005

• 3) Kojima M, Haruno R, Nakazato M et al:Purification and identification of neuromedin U as an andogenous ligand for an orphan receptor GPR 66 (FM 3). Biochem Biophys Res Commun 276:435-438, 2000

P.171 掲載の参考文献

• 1) Reik W, Walter J:Genomic imprinting:parental influence on the genome. Nat Rev Genet 2:21-32, 2001
  pubmed

• 2) Ferguson-Smith AC, Surani MA:Imprinting and the epigenetic asymmetry between parental genomes. Science 293:1086-1089, 2001
  pubmed

• 3) Werner A:Natural antisense transcripts. RNA Biol 2:53-62, 2005
  pubmed

• 4) Davies W, Isles AR, Wilkinson LS:Imprinted gene expression in the brain. Neurosci Biobehav Rev 29:421-430, 2005
  pubmed

P.173 掲載の参考文献

• 1) ケリー・L・ジャン;安藤寿康, 大野裕, 敷島千鶴ほか訳:精神疾患の行動遺伝学, 培風館, 印刷中

• 2) DeFries JC, McClearn GE, McGuffin P et al:Behavioral Genetics, 4th ed, W. H. Freeman & Co., New York, 2000

• 3) 安藤寿康:心はどのように遺伝するか-双生児が語る新しい遺伝観, 講談社, 東京, 2000

P.175 掲載の参考文献

• 1) Rutkowski DT, Kaufman RJ:A trip to the ER:coping with stress. Trends Cell Biol 14:20-28, 2004

• 2) Kondo S, Murakami T, Tatsumi K et al:OASIS, a CREB/ATF-family member, modulates UPR signalling in astrocytes. Nat Cell Biol 7:186-194, 2005
  pubmed

• 3) Murakami T, Kondo S, Ogata M et al:Cleavage of the membrane-bound transcription factor OASIS in response to endoplasmic reticulum stress. J Neurochem 96:1090-1100, 2006
  pubmed

• 4) Kondo S, Saito A, Hino S et al:BBF2H7, a novel transmembrane bZIP transcription factor, is a new type of endoplasmic reticulum stress transducer. Mol Cell Biol 27:1716-1729, 2007
  pubmed

P.177 掲載の参考文献

• 1) Okano H:Stem cell biology of the central nervous system. J Nezarosci Res 69:698-707, 2002
  pubmed

• 2) Weiss S, Dunne C, Hewson J et al:Multipotent CNS stem cells are present in the adult mammalian spinal cord and ventricular neuroaxis. J Neurosci 16:7599-7609, 1996
  pubmed

• 3) 川口綾乃, 岡野栄之:神経幹細胞の同定中枢神経系の再生を目指して. 細胞工学 19:392-397, 2000

P.179 掲載の参考文献

• 1) Elder GA, De Gasperi R, Gama Sosa MA:Research update:neurogenesis in adult brain and neuropsychiatric disorders. Mt Sinai Med 73:931-940, 2006

• 2) Kempermann G:Regulation of adult hippocampal neurogenesis-implications for novel theories of major depression. Bipolar Disord 4:17-33, 2002
  pubmed

• 3) Warner-Schmidt JL, Duman RS:Hippocampal neurogenesis:opposing effects of stress and antidepressant treatment. Hippocampus 16:239-249, 2006
  pubmed

• 4) Greenberg DA, Jin K:Neurodegeneration and neurogenesis:focus on Alzheimer's disease. Curr Alzheimer Res 3:25-28, 2006
  pubmed

P.181 掲載の参考文献

• 1) Eriksson PS, Perfilieva E, Bjork-Eriksson T et al:Neurogenesis in the adult human hippocampus. Nat Med 4:1313-1317, 1998
  pubmed

• 2) Snyder JS, Hong NS, McDonald R et al:A role for adult neurogenesis in spatial long-term memory. Neuroscience 130:843-852, 2005

• 3) Malberg J, Eisch AJ, Nestler EJ et al:Chronic antidepressant treatment increases neurogenesis in adult hippocampus. J Neurosci 20:9104-9110, 2000
  pubmed

• 4) Santarelli L, Saxe M, Gross C et al:Requirement of hippocampal neurogenisis for the behavioral effects of antidepressants. Science 301:805-809, 2003

• 5) Jung KH, Chu K, Kim M et al:Continuous cytosine-b-D-arabinofuranoside infusion reduces ectopic granule cells in adult rat hippocampus with attenuation of spontaneous recurrent seizures following pilocarpine-induced status epilepticus. Eur J Neurosci 19:3219-3226, 2000

• 6) Scharfman HE, Goodman JH, Sollas AL:Granulelike neurons at the hilar/CA 3 border after status epilepticus and their synchrony with area CA 3 pyramidal cells:functional implications of seizure-induced neurogenesis. J Neurosci 20:6144-6158, 2000

• 7) Doetsch F, Caille I, Lim DA et al:Subventricular zone astrocytes are neural stem cells in the adult mammalian brain. Cell 97:703-716, 1999
  pubmed

• 8) Seri B, Garcia-Verdugo JM, McEwen BS et al:Astrocytes give rise to new neurons in the adult mammalian hippocampus. J Neurosci 21:7153-7160, 200

P.183 掲載の参考文献

• 1) Billeter JC, Rideout EJ, Dornan AJ et al:Control of male sexual behavior in Drosophila by the sex determination pathway. Curr Biol 16:R 766-R 776, 2006

• 1) Yamamoto D:Is fruitless a master control gene for behavior?Adv Genet, in Press

P.185 掲載の参考文献

• 1) Bubar MJ, Cunningham KA:Serotonin 5-HT 2 A and 5-HT 2 C receptors as potential targets for modulation of psychostimulant use and dependence. Curr Top Med Chem 6:1971-1985, 2006

• 2) Norton N, Owen MJ:HTR 2 A:association and expression studies in neuropsychiatric genetics. Ann Med 37:121-129, 2005

P.187 掲載の参考文献

• 1) Reveley AM, Reveley MA, Clifford CA et al:Cerebral ventricular size in twins discordant for schizophrenia. Lancet 1:540-541, 1982
  pubmed

• 2) Tsujita T, Niikawa N, Yamashita H et al:Genomic discordance between monozygotic twins discordant for schizophrenia. Am J Psychiatry 155:422-424, 1998
  pubmed

• 3) Kakiuchi C, Iwamoto K, Ishiwata M et al:Impaired feedback regulation of XBP 1 as a genetic risk factor for bipolar disorder. Nat Genet 35:171-175, 2003

• 4) 辻田高宏, 岡崎祐士:遺伝研究. 臨床精神医学講座2 精神分裂病I, 松下正明総編, 中山書店, 東京, 1999, pp. 75-95

P.189 掲載の参考文献

• 1) Hutton M, Lendon CL, Rizzu P et al:Association of missense and 5-splice site mutations in tau with the inherited dementia FTDP-17. Nature 393:702-705, 1998
  pubmed

• 2) Hong M, Zhukareva V, Vogelsberg-Ragaglia V et al:Mutation-specific functional impairments in distinct tau isoforms of hereditary FTDP-17. Science 282:1914-1917, 1998
  pubmed

P.191 掲載の参考文献

• 1) Jacobsen NJ, Lyons I, Hoogendoorn B et al:ATP2A2 mutations in Darier's disease and their relationship to neuropsychiatric phenotypes. Hum Mol Genet 8:1631-1636, 1999
  pubmed

• 1) Kusumi I, Koyama T:Serotonin-2A receptor function in affective disorders. In:Signal Transduction in Affective Disorders, ed by Ozawa H, Saito T, Takahata N, Springer, Tokyo, 1998, pp. 21-34

• 2) Jacobsen NJ, Franks EK, Elvidge G et al:Exclusion of the Darier's disease gene, ATP2A2, as a common susceptibility gene for bipolar disorder. Mol Psychiatry 6:92-97, 2001
  pubmed

• 2) 本田英比古:各種疾患にみられる神経疾患奇形症候群 Darier 病. 日本臨床別冊神経症候群V:168-169, 2000

• 3) Kato T:Molecular genetics of bipolar disorder. Neurosci Res 40:105-113, 2001
  pubmed

• 4) 久住一郎, 亀田謙介, 鈴木克治ほか:Darier 病遺伝子と気分障害の病態研究. 分子精神医学 3:94-98, 2003
  Medical*Online

P.193 掲載の参考文献

• 1) Kojima T, Matsushima E, Ando K:Eyes and the mind-Psychophysiological approach to psychiatric disorders through visual and ocular functions. Japan Scientific Societies Press and Karger, Tokyo, 2000

• 2) 小島卓也:統合失調症の客観的診断と生物学的基盤. 精神神経誌 106:1175-1179, 2004

• 3) 小島卓也, 高橋栄, 泰羅雅登ら:統合失調症の認知機能, 中枢神経回路, 感受性遺伝子を基盤にした新しい診断装置の開発-探索眼球運動の臨床応用. 精神医学 49:245-252, 2007

P.196 掲載の参考文献

• 1) Hanna MG:Genetic neurological channelopathies. Nat Clin Pract Neurol 2:252-263, 2006
  pubmed

• 2) Gardiner M:Molecular genetics of infantile nervous system channelopathies. Early Hum Dev 82:775-779, 2006
  pubmed

• 3) Kaneko S, Okada M, Iwasa H et al:Genetics of epilepsy:current status and perspectives. Neurosci Res 44:11-30, 2002
  pubmed

• 4) 兼子直:バルプロ酸の作用機序. バルプロ酸の臨床薬理, 兼子直, Nau H編, ライフ・サイエンス, 東京, 2006, pp. 16-26

P.199 掲載の参考文献

• 1) Ishizuka K, Paek M, Kamiya A et al:A review of Disrupted-ln-Schizophrenia-1 (DISC 1):neuro-development, cognition, and mental conditions. Biol. Psychiatry 59:1189-1197, 2006

• 2) Millar JK, Pickard BS, Mackie S et al:DISC 1 and PDE 4 B are interacting genetic factors in schizophrenia that regulate cAMP signaling. Science 310:1187-1191, 2005

• 3) Kamiya A, Kubo K, Tomoda T et al:A schizophrenia-associated mutation of DISC 1 perturbs cerebral cortex development. Nat Cell Biol 7:1167-1178, 2005

• 4) Callicott JH, Straub RE, Pezawas L et al:Variation in DISC 1 affects hippocampal structure and function and increases risk for schizophrenia. Proc Natl Acad Sci USA 102:8627-8632, 2005

• 5) Hashimoto R, Numakawa T, Ohnishi T et al:Impact of the DISC 1 Ser 704 Cys polymorphism on risk for major depression, brain morphology and ERK signaling. Hum Mol Genet 15:3024-3033, 2006

P.201 掲載の参考文献

• 1) 橋本亮太:統合失調症関連遺伝子とその機能. 脳と精神の医学 17:37-46, 2006

• 2) 橋本亮太, 沼川忠広, 矢ケ崎有希ほか:統合失調症の病態とディスバインジン, 脳 218:29-33, 2005

• 3) 橋本亮太, 沼川忠広, 矢ケ崎有希ほか:dysbindin (DTNBP 1) . 分子精神医学 5:64-65, 2005

• 4) Harrison PJ, Weinberger DR:Schizophrenia genes, gene expression, and neuropathology:on the matter of their convergence. Mol Psychiatry 10:40-68, 2005
  pubmed

• 5) Hashimoto R, Hattori S, Chiba S et al:Susceptibility genes for schizophrenia. Psychiatry Clin Neurosci 60:S 35-S 41, 2006

P.203 掲載の参考文献

• 1) Walther DJ, Peter JU, Bashammakh S et al:Synthesis of serotonin by a second tryptophan hydroxylase isoform. Science 299:76, 2003
  pubmed

• 2) Zill P, Baghai TC, Zwanzger P et al:SNP and haplotype analysis of a novel tryptophan hydroxylase isoform (TPH2) gene provide evidence for association with major depression. Mol Psychiatry 9:1030-1036, 2004
  pubmed

• 3) Zhang X, Gainetdinov RR, Beaulieu JM et al:Loss-of-function mutation in tryptophan hydroxylase-2 identified in unipolar major depression. Neuron 45:11-16, 2005
  pubmed

• 4) Garriock HA, Allen JJ, Delgado P et al:Lack of association of TPH2 exon XI polymorphisms with major depression and treatment resistance. Mol Psychiatry 10:976-977, 2005
  pubmed

• 5) Zhou Z, Roy A, Lipsky R et al:Haplotype-based linkage of tryptophan hydroxylase 2 to suicide attempt, major depression, and cerebrospinal fluid 5-hydroxyindoleacetic acid in 4 populations. Arch Gen Psychiatry 62:1109-1118, 2005
  pubmed

• 6) Walitza S, Renner TJ, Dempfle A et al:Transmission disequilibrium of polymorphic variants in the tryptophan hydroxylase-2 gene in attention-deficit/hyperactivity disorder. Mol Psychiatry 10:1126-1132, 2005
  pubmed

• 7) Sheehan K, Lowe N, Kirley A et al:Tryptophan hydroxylase 2 (TPH2) gene variants associated with ADHD. Mol Psychiatry 10:944-949, 2005
  pubmed

P.205 掲載の参考文献

• 1) Camargo LS, Yoneyama T:Specification of training sets and the number of hidden neurons for multilayer perceptrons. Neural Comput 13:2673-2680, 2001
  pubmed

• 2) Kohonen T:Self-organizing maps, 3rd ed, Springer-Verlag, Berlin, 2001

• 3) 中田力:脳の方程式いち・たす・いち, 紀伊國屋書店, 東京, 2001

P.207 掲載の参考文献

• 1) Falls DL:Neuregulins:functions, forms, and signaling strategies. Exp Cell Res 284:14-30, 2003
  pubmed

• 2) Corfas G, Roy K, Buxbaum JD:Neuregulin 1-erbB signaling and the molecular/cellular basis of schizophrenia. Nature Neurosci 7:575-580, 2004
  pubmed

• 3) Harrison PJ, Law AJ:Neuregulin 1 and schizophrenia:genetics, gene expression, and neurobiology. Biol Psychiatry 60:132-140, 2006
  pubmed

P.209 掲載の参考文献

• 1) Hashimoto K, Shimizu E, Iyo M:Critical role of brain-derived neurotrophic factor in mood disorders. Brain Res Brain Res Rev 45:104-114, 2004
  pubmed

• 2) Hashimoto K, Koizumi H, Nakazato M et al:Role of brain-derived neurotrophic factor in eating disorders:recent findings and its pathophysiological implications. Prog Neuropharmacol Biol Psychiatry 29:499-504, 2005

• 3) Hashimoto K:BDNF variant Iinked to anxietyelated behaviors. Bioessays 29:116-119, 2007

P.212 掲載の参考文献

• 1) Bonisch H, Bruss M:The norepinephrine transporter in physiology and disease. Handb Exp Pharmacol 175:485-524, 2006
  pubmed

• 2) NCBI:Solute carrier family 6 (neurotransmitter transporter, noradrenaline), member 2;SLC6A2. OMIM (URL:http://www.ncbi.nlm.nih.gov/entrez/dispomim.cgi?id=163970)

• 3) Lin Z, Madras BK:Human genetics and pharmacology of neurotransmitter transporters. Handb Exp Pharmacol 175:327-371, 2006
  pubmed

• 4) 北山滋雄, 土肥敏博:ノルエピネフリントランスポーター. 薬物動態・作用と遺伝子多型, 澤田康文編, 医薬ジャーナル社, 大阪, 2001, pp. 440-447

• 5) 土肥敏博, 北山滋雄, 熊谷圭ほか:モノアミントランスポーターの薬理学. 日本薬理学雑誌,120:315-326, 2002
  Medical*Online

P.215 掲載の参考文献

• 1) Vaudry D, Gonzalez BJ, Basille M et al:Pituitary adenylate cyclase-activating polypeptide and its receptors:from structure to functions. Pharmacol Rev 52:269-324, 2000
  pubmed

• 2) 新谷紀人:PACAP 遺伝子欠損マウスの脳機能変化. 薬学雑誌 124:667-671, 2004

• 3) 新谷紀人, 橋本均, 馬場明道:新しいGPCRリガンド研究の現状と展望〜神経ペプチドPACAPの生理機能. ホルモンと臨床 55:131-139, 2007

• 4) 橋本均, 新谷紀人, 馬場明道:ニューロペプチド PACAPと精神神経機能:変異マウスからの予想外の知見. 生化学 79:26-30, 2007

• 5) Hashimoto H, Shintani N, Baba A:New insights into the central PACAPergic system from the phenotypes in PACAP-and PACAP receptor-knockout mice. Ann N Y. Acad Sci 1070:75-89, 2006
  pubmed

• 6) Hashimoto H, Shintani N, Baba A:Higher brain functions of PACAP and a homologous Drosophila memory gene amnesiac:insights from knockouts and mutants. Biochem Biophys Res Commun 297:427-431, 2002

• 7) 馬場明道, 新谷紀人, 松田敏夫:創薬標的分子の探索・評価. 次世代ゲノム創薬, 日本薬学会編, 中山書店, 東京, 2003, pp. 45-63

• 8) Shintani N, Tomimoto S, Hashimoto H et al:Functional roles of the neuropeptide PACAP in brain and pancreas. Life Sci 74:337-343, 2003
  pubmed

• 9) Hattori T, Baba K, Matsuzaki S et al:A novel DISC 1-interacting partner DISC 1-Binding Zinc-finger protein:implication in the modulation of DISC 1-dependent neurite outgrowth. Mol Psychiatry 12:398-407, 2007

• 10) Hashimoto R, Hashimoto H, Shintani N et al:Pituitary Adenylate cyclase-activating polypeptide is associated with schizophrenia. Mol Pyschiatry 2007 (Epub ahead of print)

P.219 掲載の参考文献

• 1) Pearson CE, Edamura KN, Cleary JD:Repeat in stability:mechanisms of dynamic mutations. Nature Reviews Genet 6:729-742, 2005

• 2) Brown LY, Brown SA:Alanine tracts:the expanding story of human Illness and trinucleotide repeats. TRENDS in Genet 20:51-58, 2004
  pubmed

• 3) Pieretti M, Zhang F, Fu YH et al:Absence of expression of the FMR-1 gene in fragile X syndrome. Cell 66:817-822, 1991
  pubmed

• 4) Timchenko LT, Caskey CT:Trinucleotide repeat disorders in humans:discussions of mechanisms and medical issues. FASEB J 10:1589-1597, 1996
  pubmed

• 5) Erdmann VA, Barciszewska MZ, Szymanski M et al:The non-coding RNAs as riboregulators. Nucleic Acids Res 29:189-193, 2001
  pubmed

• 6) Komure O, Sano A, Nishino N et al:DNA analysis in hereditary dentatorubral-pallidoluysian atrophy:correlation between CAG repeat length and phenotypic variation and the molecular basis of anticipation. Neurology 45:143-149, 1995
  pubmed

• 7) La Spada AR, Paulson HL, Fischbeck KH:Trinucleotide repeat expansion in neurological disease. Ann Neurol 36:814-822, 1994
  pubmed

• 8) Toyota T, Yoshitsugu K, Ebihara M et al:Association between schizophrenia with ocular misalignment and polyalanine length variation in PMX 2B. Hum Mol Genet 13:551-561, 2004

• 9) Pearson CE:Slipping while sleeping? Trinucleotide repeat expansions in germ cells. Trends Mol Med 9:490-495, 2003
  pubmed

• 10) Ueno S, Kondoh K, Kotani Y et al:Somatic mosaicism of CAG repeat in dentatorubral-pallidoluysian atrophy (DRPLA) . Hum Molec Genet 4:663-666, 1995
  pubmed

• 11) Karayiorgou M, Gogos JA:A turning point in schizophrenia genetics. Neuron 19:967-979, 1997

• 12) Cadoret RJ:Evidence for genetic inheritance of primary affective disorder in adoptees. . Am J Psychiat 135:463-466, 1978
  pubmed

• 13) Morel BA:Traite des degenerescences, JB Bailliere, Paris, 1857

• 14) Bassett AS, Honer WG:Evidence for anticipation in schizophrenia. Am J Hum Genet 54:864-870, 1994
  pubmed

• 15) McInnis MG, McMahon FJ, Chase GA et al:Anticipation in bipolar affective disorder. Am Hum Genet 53:385-390, 1993
  pubmed

• 16) 0'Donovan MC, Guy C, Craddock N et al:Expanded CAG repeats in schizophrenia and bipolar disorder. Nat Genet 10:380-381, 1995

• 17) Oruc L, Lindblad K, Verheyen GR et al:CAG repeat expansions in bipolar and unipolar disorders. Am Hum Genet 60:730-732, 1997
  pubmed

• 18) Del-Favero J, Gestel SV, Borglum AD et al:European combined analysis of the CTG 18.1 and the ERDA 1 CAG/CTG repeats in bipolar disorder. Eur J Hum Genet 10:276-280, 2002

• 19) Tsutsumi T, Holmes SE, Mclnnis MG et al:Novel CAG/CTG repeat expansion mutations do not contribute to the genetic risk for most cases of bipolar disorder or schizophrenia. Am J Med Genet B 124:15-19, 2004
  pubmed

P.221 掲載の参考文献

• 1) Braff DL, Geyer MA, Swerdlow NR:Human studies of prepulse inhibition of startle:normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl) 156:234-258, 2001
  pubmed

• 1) 功刀浩, 柳沢洋美, 田中美穂ほか:統合失調症とうつ病におけるプレパルスインヒビションと関連指標:予備的報告. 精神医学 49:253-260, 2007

• 2) Geyer MA, Krebs-Thomson K, Braff DL et al:Pharmacological studies of prepulse inhibition models of sensorimotor gating deficits in schizophrenia:a decade in review. Psychopharmacology (Berl) 156:117-154, 2001
  pubmed

• 3) Starlle modzfication:implications for neuroscience, cognitive science, and clinical science, ed by Dawson ME, Schell AM, Bohmelt AH, Cambridge University Press, New York, 1999

P.222 掲載の参考文献

• 1) Rizzolatti G, Fadiga L, Gallese V et al:Premotor cortex and the recognition of motor actions. Brain Res Cogn Brain Res 3:131-141, 1996
  pubmed

• 2) Blakemore SJ, Decety J:From the perception of action to the understanding of intention. Nat Rev Neurosci 2:561-567, 2001

• 3) Ohnishi T, Moriguchi Y, Matsuda H et al:The neural network for the mirror system and mentalizing in normally developed children:an fMRI study. Neuroreport 15:1483-1487, 2004
  pubmed

• 4) Dapretto M, Davies MS, Pfeifer JH et al:Understanding emotions in others:mirror neuron dysfunction in children with autism spectrum disorders. Nat Neurosci 9:28-30, 2006
  pubmed

P.225 掲載の参考文献

• 1) 重藤寛史:脳磁図の基礎と臨床応用. 第42回日本臨床神経生理学会技術講習会テキスト, 2005, pp. 65-71

• 2) 平野昭吾, 鬼塚俊明, 神庭重信:統合失調症のMEG研究. 精神科 9:200-204, 2006

P.227 掲載の参考文献

• 1) ユビキチンがわかる (わかる実験医学シリーズ), 田中啓二編, 羊土社, 東京, 2004

• 2) ユビキチン・プロテアソーム系とオートファジー:作動機構と病態生理. 蛋白質核酸酵素, 田中啓二, 大隅良典編, 共立出版, 東京, 2006

P.229 掲載の参考文献

• 1) 仲嶋一範:大脳皮質構築とリーリン. Annual Review 神経 2003:10-17, 2003

• 1) Guidotti A, Auta J, Davis JM et al:Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder:a postmortem brain study. Arch Gen Psychiatry 57:1061-1069, 2000
  pubmed

• 2) Liu WS, Pesold C, Rodriguez MA et al:Down-regulation of dendritic spine and glutamic acid decarboxylase 67 expressions in the reelin haploinsufficient heterozygous reeler mouse. Proc natl Acad Sci USA 98:3477-3482, 2001
  pubmed

• 2) 森本桂子, 仲嶋一範:発生期大脳皮質におけるニューロンの移動と配置のダイナミクス. 実験医学25:338-345, 2007

• 3) 仲嶋一範, 本田岳夫, 久保健一郎:神経系の後期発生-脳皮質構造の形成-脳神経外科学大系 第一巻「神経科学」河瀬斌編, 中山書店, 東京, 2006, pp.22-34

• 3) Grayson DR, Jia X, Chen Y et al:Reelin promoterhypermethylation in schizophrenia. Proc natl Acad Sci USA 102:9341-9346, 2005

• 4) Herz J, Chen Y:Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Nezarosci 11:350-359, 2006

P.231 掲載の参考文献

• 1) 橋本亮太, 安田由華, 大井一高ほか:気分安定薬の作用メカニズム. こころの科学 131:47-52, 2007

• 2) Chuang DM:The antiapoptotic actions of mood stabilizers:molecular mechanisms and therapeutic potentials. Ann NY Acad Sci 1053:195-204, 2005
  pubmed

• 3) 橋本亮太:気分安定薬の作用機序の新しい知見. 精神科治療学 20:1091-1098, 2005

• 4) 橋本亮太:リチウムの神経保護効果. 分子精神医学 3:72-73, 2003

• 5) Chuang DM, Chen RW, Chalecka-Franaszek E et al:Neuroprotective effects of lithium in cultured cells and animal models of diseases. Bipolar Disord 4:129-136, 2002
  pubmed